| Literature DB >> 33634874 |
Pek Kei Im1, Iona Y Millwood1,2, Christiana Kartsonaki1,2, Yiping Chen1,2, Yu Guo3, Huaidong Du1,2, Zheng Bian3, Jian Lan4, Shixian Feng5, Canqing Yu6, Jun Lv6, Robin G Walters1,2, Liming Li6, Ling Yang1,2, Zhengming Chen1,2.
Abstract
Alcohol drinking is associated with increased risks of several site-specific cancers, but its role in many other cancers remains inconclusive. Evidence is more limited from China, where cancer rates, drinking patterns and alcohol tolerability differ importantly from Western populations. The prospective China Kadoorie Biobank recruited >512 000 adults aged 30 to 79 years from 10 diverse areas during 2004 to 2008, recording alcohol consumption patterns by a standardised questionnaire. Self-reported alcohol consumption was estimated as grams of pure alcohol per week based on beverage type, amount consumed per occasion and drinking frequency. After 10 years of follow-up, 26 961 individuals developed cancer. Cox regression was used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) relating alcohol consumption to incidence of site-specific cancers. Overall, 33% (n = 69 734) of men drank alcohol regularly (ie, ≥weekly) at baseline. Among male current regular drinkers, alcohol intake showed positive dose-response associations with risks of cancers in the oesophagus (655 events; HR = 1.98 [95%CI 1.79-2.18], per 280 g/wk), mouth and throat (236; 1.74 [1.48-2.05]), liver (573; 1.52 [1.31-1.76]), colon-rectum (575; 1.19 [1.00-1.43]), gallbladder (107; 1.60 [1.16-2.22]) and lung (1017; 1.25 [1.10-1.42]), similarly among never- and ever-regular smokers. After adjustment for total alcohol intake, there were greater risks of oesophageal cancer in daily drinkers than nondaily drinkers and of liver cancer when drinking without meals. The risks of oesophageal cancer and lung cancer were greater in men reporting flushing after drinking than not. In this male population, alcohol drinking accounted for 7% of cancer cases. Among women, only 2% drank regularly, with no clear associations between alcohol consumption and cancer risk. Among Chinese men, alcohol drinking is associated with increased risks of cancer at multiple sites, with certain drinking patterns (eg, daily, drinking without meals) and low alcohol tolerance further exacerbating the risks.Entities:
Keywords: China; alcohol; cancer; cohort studies; drinking patterns
Mesh:
Year: 2021 PMID: 33634874 PMCID: PMC8359462 DOI: 10.1002/ijc.33538
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396
Baseline characteristics of participants by alcohol drinking categories in men
| Current regular drinkers | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Overall | Abstainers | Ex‐regular drinkers | Occasional drinkers | All current regular | <140 g/wk | 140–279 g/wk | 280–419 g/wk | 420+ g/wk | |
| Number of participants | 209 237 | 42 479 | 18 061 | 78 963 | 69 734 | 24 999 | 18 874 | 12 811 | 13 050 |
| Sociodemographic characteristics | |||||||||
| Mean age, y (SD) | 52.8 (10.9) | 56.3 (11.1) | 56.9 (10.3) | 51.2 (10.8) | 51.5 (10.2) | 51.7 (11.1) | 51.9 (10.2) | 51.2 (9.6) | 51.4 (9.5) |
| Urban area, % | 43.4 | 31.1 | 41.0 | 44.1 | 49.9 | 58.8 | 52.3 | 47.9 | 30.8 |
| Educational attainment >6 y, % | 57.8 | 54.5 | 56.7 | 60.5 | 57.7 | 60.7 | 57.1 | 57.9 | 53.9 |
| Income >20 000 yuan/y, % | 45.7 | 42.0 | 45.0 | 46.7 | 46.8 | 47.8 | 46.3 | 45.4 | 46.8 |
| Married, % | 92.9 | 91.4 | 93.4 | 93.3 | 93.3 | 94.0 | 93.3 | 93.3 | 92.1 |
| Lifestyle factors | |||||||||
| Regular smoking, % | 61.2 | 52.5 | 60.8 | 56.9 | 71.8 | 65.8 | 73.1 | 76.4 | 79.9 |
| Daily fresh fruit consumption, % | 23.0 | 24.9 | 25.3 | 25.2 | 21.1 | 25.2 | 20.3 | 17.8 | 15.8 |
| Physical activity, mean MET‐h/d (SD) | 22.1 (15.3) | 21.2 (15.1) | 20.3 (14.5) | 22.6 (15.6) | 22.4 (15.0) | 22.7 (15.1) | 23.1 (14.9) | 23.3 (15.4) | 22.8 (15.2) |
| Daily tea drinking, % | 40.9 | 36.1 | 40.3 | 37.3 | 48.5 | 45.8 | 47.8 | 49.0 | 52.5 |
| Physical measurements, mean (SD) | |||||||||
| Body mass index, kg/m2 | 23.4 (3.2) | 23.3 (3.2) | 23.9 (3.4) | 23.4 (3.2) | 23.4 (3.2) | 23.7 (3.2) | 23.7 (3.2) | 23.7 (3.2) | 23.7 (3.2) |
| Systolic blood pressure, mmHg | 132.8 (20.0) | 132.4 (21.5) | 134.4 (21.5) | 131.0 (18.8) | 134.8 (19.8) | 131.6 (21.5) | 134.3 (19.8) | 136.0 (19.9) | 137.4 (20.7) |
| Diastolic blood pressure, mmHg | 79.2 (11.4) | 78.6 (11.5) | 80.0 (11.7) | 78.1 (10.9) | 80.6 (11.5) | 79.5 (11.5) | 81.0 (11.5) | 82.2 (11.6) | 83.0 (11.7) |
| Health and medical history, % | |||||||||
| Poor health | 8.8 | 12.5 | 16.9 | 7.6 | 5.8 | 6.0 | 5.9 | 5.4 | 6.6 |
| Any chronic disease | 22.2 | 26.6 | 37.1 | 20.9 | 17.7 | 18.9 | 17.6 | 17.1 | 17.7 |
| Coronary heart disease | 2.7 | 3.3 | 5.2 | 2.3 | 2.0 | 2.2 | 1.9 | 1.7 | 2.3 |
| Stroke/transient ischaemic attack | 2.3 | 3.6 | 6.0 | 1.6 | 1.3 | 1.4 | 1.3 | 1.1 | 1.3 |
| Liver cirrhosis/chronic hepatitis | 1.7 | 2.7 | 3.8 | 1.6 | 1.2 | 1.1 | 1.2 | 1.2 | 1.5 |
| Emphysema/bronchitis | 3.1 | 3.9 | 4.7 | 2.7 | 2.5 | 2.5 | 2.6 | 2.2 | 2.7 |
| Chronic obstructive pulmonary disease | 8.8 | 10.4 | 10.8 | 7.7 | 8.3 | 8.0 | 8.5 | 7.7 | 9.7 |
| Diabetes | 5.5 | 6.6 | 8.8 | 5.0 | 4.6 | 4.6 | 4.4 | 5.0 | 5.6 |
| Family history of cancer | 16.5 | 14.6 | 18.0 | 16.5 | 17.2 | 16.9 | 17.4 | 17.6 | 17.7 |
Note: Participants with self‐reported prior cancer were excluded. Prevalences and means are adjusted for age and study areas as appropriate.
Abbreviation: MET‐h/d, metabolic equivalents of task per hours per day.
All self‐reported except for chronic obstructive pulmonary disease and diabetes, which included both self‐reported and screen‐detected events.
Chronic diseases included self‐reported coronary heart disease, stroke, transient ischaemic attack, diabetes, tuberculosis, chronic hepatitis/liver cirrhosis, rheumatoid arthritis, peptic ulcer, emphysema/bronchitis, gallstone/gallbladder disease and kidney disease.
Adjusted hazard ratios (HRs) for incident cancers associated with alcohol drinking status in men
| Abstainers | Ex‐regular drinkers | Occasional drinkers | Current regular drinkers | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancer site | All men N | N | HR (95% CI) | N | HR (95% CI) | N | HR (95% CI) | N | HR (95% CI) |
| HR (95% CI) per 280 g/wk |
|
| Mouth and throat | 541 | 90 | 1.00 (0.81‐1.24) | 61 | 1.46 (1.13‐1.88) | 154 | 1.22 (1.03‐1.44) | 236 | 1.73 (1.51‐1.99) | <.001 | 1.74 (1.48‐2.05) | <.001 |
| Oesophagus | 1608 | 243 | 1.00 (0.88‐1.14) | 152 | 1.23 (1.05‐1.44) | 558 | 1.05 (0.96‐1.15) | 655 | 1.80 (1.66‐1.96) | <.001 | 1.98 (1.79‐2.18) | <.001 |
| Colon and rectum | 1527 | 306 | 1.00 (0.89‐1.13) | 203 | 1.27 (1.10‐1.46) | 443 | 0.95 (0.86‐1.05) | 575 | 1.20 (1.10‐1.31) | .02 | 1.19 (1.00–1.43) | .051 |
| Colon | 856 | 180 | 1.00 (0.86‐1.17) | 118 | 1.28 (1.06‐1.53) | 255 | 0.93 (0.81‐1.05) | 303 | 1.11 (0.98‐1.25) | .31 | 1.13 (0.87–1.45) | .36 |
| Rectum | 946 | 185 | 1.00 (0.86‐1.16) | 122 | 1.22 (1.02‐1.46) | 261 | 0.93 (0.82‐1.06) | 378 | 1.26 (1.13‐1.40) | .02 | 1.29 (1.04–1.58) | .02 |
| Liver | 1651 | 378 | 1.00 (0.90‐1.11) | 208 | 1.23 (1.07‐1.41) | 492 | 0.83 (0.76‐0.92) | 573 | 1.06 (0.97‐1.16) | .39 | 1.52 (1.31–1.76) | <.001 |
| Stomach | 2221 | 520 | 1.00 (0.91‐1.10) | 242 | 1.00 (0.88‐1.13) | 702 | 0.87 (0.81‐0.95) | 757 | 1.02 (0.94‐1.10) | .77 | 1.11 (0.94‐1.30) | .22 |
| Pancreas | 405 | 89 | 1.00 (0.80‐1.25) | 40 | 0.96 (0.70‐1.32) | 111 | 0.97 (0.80‐1.18) | 165 | 1.26 (1.07‐1.49) | .10 | 1.20 (0.86‐1.66) | .28 |
| Lung | 2741 | 660 | 1.00 (0.92‐1.08) | 344 | 1.07 (0.97‐1.20) | 720 | 0.80 (0.74‐0.86) | 1017 | 0.96 (0.90‐1.03) | .48 | 1.25 (1.10–1.42) | <.001 |
| Gallbladder and biliary tract | 279 | 54 | 1.00 (0.76‐1.32) | 29 | 1.02 (0.71‐1.48) | 89 | 1.31 (1.05‐1.64) | 107 | 1.33 (1.09‐1.62) | .11 | 1.60 (1.16–2.22) | .004 |
| Skin | 137 | 41 | 1.00 (0.72‐1.39) | 17 | 1.00 (0.61‐1.62) | 44 | 0.83 (0.61‐1.14) | 35 | 0.65 (0.46‐0.92) | .08 | 0.80 (0.36‐1.81) | .60 |
| Prostate | 402 | 110 | 1.00 (0.82‐1.22) | 64 | 1.25 (0.97‐1.60) | 120 | 1.00 (0.83‐1.21) | 108 | 0.89 (0.73‐1.08) | .41 | 1.17 (0.77‐1.77) | .47 |
| Kidney | 219 | 34 | 1.00 (0.70‐1.43) | 28 | 1.52 (1.04‐2.21) | 73 | 1.15 (0.91‐1.47) | 84 | 1.27 (1.01‐1.60) | .26 | 1.42 (0.90‐2.23) | .13 |
| Bladder | 356 | 89 | 1.00 (0.80–1.25) | 57 | 1.14 (0.88‐1.49) | 96 | 0.73 (0.60‐0.91) | 114 | 0.75 (0.61‐0.90) | .053 | 0.84 (0.52‐1.34) | .46 |
| Brain | 227 | 48 | 1.00 (0.74‐1.35) | 29 | 1.12 (0.77‐1.62) | 80 | 0.92 (0.73‐1.16) | 70 | 0.82 (0.64‐1.04) | .31 | 1.35 (0.89‐2.07) | .16 |
| Thyroid | 84 | 12 | 1.00 (0.55‐1.82) | 10 | 1.66 (0.88‐3.13) | 27 | 0.96 (0.65‐1.43) | 35 | 1.18 (0.83‐1.68) | .63 | 1.10 (0.55‐2.22) | .78 |
| Lymphoma | 402 | 104 | 1.00 (0.82‐1.23) | 49 | 1.02 (0.77‐1.36) | 115 | 0.88 (0.73‐1.07) | 134 | 0.92 (0.77‐1.10) | .56 | 1.24 (0.91‐1.69) | .18 |
| Multiple myeloma | 137 | 34 | 1.00 (0.70‐1.43) | 10 | 0.62 (0.33‐1.16) | 44 | 0.89 (0.65‐1.21) | 49 | 1.01 (0.75‐1.36) | .96 | 1.46 (0.86‐2.51) | .16 |
| Leukaemia | 287 | 63 | 1.00 (0.77‐1.30) | 31 | 1.15 (0.80‐1.64) | 86 | 0.87 (0.70‐1.09) | 107 | 1.14 (0.94‐1.40) | .43 | 1.52 (1.08‐2.12) | .01 |
| Other less common cancers of known sites | 935 | 208 | 1.00 (0.87‐1.15) | 122 | 1.21 (1.01‐1.45) | 280 | 0.94 (0.83‐1.06) | 325 | 1.05 (0.94‐1.18) | .60 | 1.08 (0.85‐1.37) | .54 |
| IARC alcohol‐related cancers | 5403 | 1056 | 1.00 (0.94‐1.07) | 673 | 1.30 (1.20‐1.40) | 1669 | 0.92 (0.88‐0.97) | 2005 | 1.26 (1.20‐1.32) | <.001 | 1.65 (1.53–1.77) | <.001 |
| Other cancers of known sites (non‐IARC alcohol‐related) | 8730 | 2085 | 1.00 (0.96‐1.05) | 1076 | 1.07 (1.00‐1.13) | 2523 | 0.87 (0.83‐0.90) | 3046 | 0.99 (0.95‐1.03) | .76 | 1.17 (1.09–1.27) | <.001 |
| All cancers | 13 342 | 2991 | 1.00 (0.96‐1.04) | 1647 | 1.14 (1.08‐1.20) | 3947 | 0.88 (0.85‐0.91) | 4757 | 1.07 (1.04‐1.10) | .006 | 1.37 (1.30‐1.45) | <.001 |
Note: Cox models are stratified by age at risk and study area, and adjusted for education, income, smoking, physical activity, fruit intake, body mass index and family history of cancer. Participants with self‐reported prior cancer were excluded from all analyses. Participants with self‐reported prior chronic hepatitis/liver cirrhosis were further excluded from analysis of liver cancer, and participants with self‐reported prior tuberculosis, emphysema/bronchitis or chronic obstructive pulmonary disease were further excluded from analysis of lung cancer.
Abbreviations: CI, confidence interval; HR, hazard ratio; IARC, International Agency for Research on Cancer.
P value for association comparing current regular drinkers vs abstainers.
P value for alcohol consumption (g/wk) modelled as a continuous variable among current regular drinkers.
The association with alcohol intake among current regular drinkers appeared nonlinear for oesophageal cancer (P < .0001), brain cancer (P = .027), IARC alcohol‐related cancer (P = .003), other cancers of known sites (P = .002) and total cancer (P = .006).
All cancers included ill‐defined neoplasm and are patient‐based.
FIGURE 1Associations of alcohol consumption with common cancers in male current regular drinkers. Cox models are stratified by age at risk and study area, and adjusted for education, income, smoking status, physical activity, fresh fruit intake, body mass index and family history of cancer. A‐D, Classified as IARC alcohol‐related cancers. Each solid square represents HR with the area inversely proportional to the “floated” variance of the log HR. The vertical lines indicate group‐specific 95% CIs. The numbers above the error bars are the point estimates for HRs, and the numbers below are the number of events. Alcohol intake is classified based on baseline consumption of <140, 140 to 279, 280 to 419 and ≥420 g/wk. P for trend is estimated by modelling alcohol consumption (g/wk) as a continuous variable among current regular drinkers. CI, confidence interval; HR, hazard ratio; IARC, International Agency for Research on Cancer
FIGURE 2Associations of alcohol consumption with IARC alcohol‐related cancers and other cancers by smoking status in male current regular drinkers. Conventions are as in Figure 1. IARC, International Agency for Research on Cancer
FIGURE 3Adjusted HRs for IARC alcohol‐related cancers associated with drinking patterns in male current regular drinkers. Cox models are stratified by age at risk and study area, and adjusted for education, income, smoking status, physical activity, fresh fruit intake, body mass index and family history of cancer, and total weekly intake where indicated. Heavy episodic drinking (HED) is defined as drinking >60 g/session. Conventions are as in Figure 1. CI, confidence interval; HR, hazard ratio; IARC, International Agency for Research on Cancer
FIGURE 4Joint associations of alcohol consumption and flushing status with oesophageal cancer and lung cancer in male current regular drinkers. Alcohol intake, separately in men reporting flushing and in others reporting no flushing, is classified based on baseline consumption of <140, 140 to 419 and ≥420 g/wk. Conventions are as in Figure 1